Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 226-229

  Bogenberger, James M ^a   Delman, Devora ^a   Hansen, Nanna ^a   Valdez, Riccardo ^a   Fauble, Veena ^a   Mesa, Ruben A ^a   Tibes, Raoul ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ABT-737; ANTINEOPLASTIC AGENT; AZACITIDINE; BIPHENYL DERIVATIVE; FUSED HETEROCYCLIC RINGS; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; SULFONAMIDE;

ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM; MYELOID LEUKEMIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOID; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84922360342     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.910657     Document Type: Letter

References (13)

1. Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014 Jan 23. [Epub ahead of print]
2. Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol 2012;91:1861-1870.
3. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362-375.
4. Bogenberger JM, Pierceall WE, Lena R, et al. BH3 prof ling predicts 5-azacytidine response in malignant myeloid cells. Blood 2012; 120(Suppl. 1): Abstract 1432.
5. Tibes R, Kornblau SM, Pierceall WE, et al. BH3 prof ling as predictor of 5-azacytidine and decitabine clinical responses. Blood 2013;122:603.
6. Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564-571.
7. Zeuner A, Pedini F, Francescangeli F, et al. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 2009;113:1522-1525.
8. Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012;26:120-125.
9. Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005;307:1101-1104.
10. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-365.
11. Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol 2013; 23: 612-619.
12. Seymour JF, Davids MS, Pagel JM, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013; 31(Suppl.): Abstract 7018.
13. Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013; 12: 329-341.